Hikal Limited (NSE:HIKAL)
India
· Delayed Price · Currency is INR 416.65
-0.25 (-0.06%)
Apr 24, 2025, 3:30 PM IST
Hikal Revenue
Hikal had revenue of 4.48B INR in the quarter ending December 31, 2024, with 0.03% growth. This brings the company's revenue in the last twelve months to 18.22B, up 0.31% year-over-year. In the fiscal year ending March 31, 2024, Hikal had annual revenue of 17.85B, down -11.79%.
Revenue (ttm)
18.22B
Revenue Growth
+0.31%
P/S Ratio
2.82
Revenue / Employee
8.84M
Employees
2,061
Market Cap
51.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 17.85B | -2.38B | -11.79% |
| Mar 31, 2023 | 20.23B | 803.09M | 4.13% |
| Mar 31, 2022 | 19.43B | 2.22B | 12.92% |
| Mar 31, 2021 | 17.20B | 2.13B | 14.14% |
| Mar 31, 2020 | 15.07B | -823.46M | -5.18% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Hikal News
- 2 months ago - Hikal shares drop over 6% after US FDA issues six observations for Jigani facility - Business Upturn
- 2 months ago - Hikal receives 6 observations for Jigani facility from US FDA - Business Upturn